RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS

Medicine & Life Sciences

1. Stomach Neoplasms 100%
2. Gastrointestinal Agents 84%
3. Curcumin 80%
4. Chemoprevention 69%
5. Placebos 49%
6. Carcinogenesis 47%
7. Incidence 17%
8. Diarylheptanoids 13%
9. Antioxidants 13%
10. Central America 12%
11. Northern Africa 12%
12. Eastern Europe 11%
13. Rhizome 11%
14. Atrophic Gastritis 11%
15. Lipoxygenase 11%
16. Curcuma 11%
17. Neoplasms 11%
18. Lecithins 11%
19. South America 10%
20. Far East 10%
21. Quality-Adjusted Life Years 9%
22. Metaplasia 9%
23. Phytochemicals 9%
24. Prostaglandin-Endoperoxide Synthases 9%
25. Intestinal Mucosa 9%
26. Flavonoids 9%
27. Arachidonic Acid 8%
28. Liposomes 8%
29. DNA Damage 7%
30. Cause of Death 7%
31. Survival Rate 6%
32. Stomach 6%
33. Research Personnel 6%
34. Inflammation 5%